Superior Planning, LLC’s Vaxcyte PCVX Stock Holding History

Superior Planning, LLC’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.53K	Buy	+62	New	+$3.61K	﹤0.01%	1340

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Superior Planning, LLC's PCVX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Vaxcyte (PCVX) in Q3 2026: 62 shares worth $3.53K. The stake represents ﹤0.01% of the portfolio and ranks #1340 among its holdings.

202 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

Superior Planning, LLC held 62 shares of Vaxcyte worth $3.53K as of Q3 2026.
Vaxcyte was a new Superior Planning, LLC position in Q3 2026.
Vaxcyte made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1340 holding.
202 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.